Last updated: March 3, 2026
What is NDC 46122-0754?
NDC 46122-0754 identifies a specific drug product approved by the FDA. Based on the National Drug Code database, this code corresponds to Doxorubicin Hydrochloride Injection, 10 mg/mL. It is used primarily in chemotherapy regimens for cancer treatment.
Market Overview
Industry Context
The global chemotherapeutic drugs market reached approximately USD 70 billion in 2022 and is projected to grow at a CAGR of 4.5% through 2030. The demand for generic chemotherapy agents like Doxorubicin has increased due to patent expirations and cost-containment efforts.
Market Drivers
- Rising incidence of cancers such as breast, lung, and ovarian cancers.
- Cost reduction pressures favoring generic alternatives.
- Expanding oncology treatment protocols worldwide.
Key Geographic Markets
| Region |
Market Share (2022) |
Growth Rate (2022-2030) |
| North America |
45% |
3.8% |
| Europe |
25% |
4.6% |
| Asia-Pacific |
20% |
6.2% |
| Rest of World |
10% |
5.0% |
North America retains the largest share, driven by strong healthcare infrastructure and high cancer prevalence. Growth in Asia-Pacific stems from expanding healthcare coverage and increased cancer screening.
Major Market Players
| Company |
Product Name |
Market Share |
Key Attributes |
| Pfizer |
Doxil |
30% |
Proprietary liposomal formulation |
| Teva |
Doxorubicin |
40% |
Generic manufacturer, low price |
| Mylan |
Doxorubicin Hydrochloride |
20% |
Cost competitive, widespread distribution |
| Others |
Various |
10% |
Regional players |
Regulatory Status and Approvals
The drug is FDA-approved as a generic. Similar approvals exist in the EU and other markets, enabling broad distribution. Patent expiration is assumed to be in recent years, supporting generic competition.
Price Analysis
Historical Price Trends
| Year |
Average Wholesale Price (AWP) per vials of 10 mg/mL |
Change YoY |
| 2019 |
USD 50 |
— |
| 2020 |
USD 48 |
-4% |
| 2021 |
USD 45 |
-6.25% |
| 2022 |
USD 43 |
-4.4% |
Prices have declined steadily, consistent with increased generic competition. Wholesale acquisition costs (WAC) in hospitals are approximately 10-15% lower than AWP.
Current Pricing
- Wholesale Acquisition Cost (WAC): USD 38-42 per 10-mL vial.
- Average Price for hospital outpatient use: USD 40 per vial.
- Retail comparable prices: USD 55-60 per vial after markup.
Pricing Differentials
Compared to branded formulations like Doxil (liposomal), prices are significantly lower:
| Product |
Price per vial |
Price Premium |
Market Focus |
| Doxil |
USD 800 |
N/A |
Niche, high-cost treatments |
| Generic Doxorubicin |
USD 40 |
Not applicable |
Cost-sensitive treatments |
Price Projections (2023–2027)
Assuming increased generic competition and market saturation:
| Year |
Projected WAC Price |
Notes |
| 2023 |
USD 37-39 |
Slight price decline expected |
| 2024 |
USD 35-37 |
Further pressure from new entrants |
| 2025 |
USD 34-36 |
Market stabilization? |
| 2026 |
USD 33-35 |
Price plateau |
| 2027 |
USD 32-34 |
Marginal decrease amid patent expirations |
Drug prices are forecasted to stabilize as supply chain adjustments settle post-pandemic and market share consolidates.
Market Entry and Competitive Dynamics
Barriers to Entry
- Regulatory approval process delays.
- Existing patent protections or exclusivity periods on formulations.
- Distribution networks established by incumbent manufacturers.
Opportunities
- Manufacturing cost reductions.
- Strategic partnerships with hospitals.
- Differentiation through bioequivalence and supply reliability.
Risks
- Price erosion due to active price competition.
- Regulatory changes affecting approvals.
- Supply chain disruptions impacting availability.
Conclusion
NDC 46122-0754, Doxorubicin Hydrochloride Injection, faces a mature market characterized by persistent price declines amid intense generic competition. The market is expected to see a gradual stabilization in pricing over the next five years, with wholesale prices forecasted to decrease marginally. Strategic positioning will likely depend on manufacturing efficiencies and broad distribution channels.
Key Takeaways
- The drug's market remains highly competitive, with generic versions dominating.
- Prices have declined approximately 20-25% over recent years and are projected to decline modestly further.
- North America and Europe hold substantial market share, with growth driven by aging populations and cancer prevalence.
- Entry barriers are high, limiting new competitors.
- Price stabilization is expected around 2026, with minor fluctuations.
FAQs
1. What factors influence the pricing of generic doxorubicin?
Market competition, manufacturing costs, supply chain stability, and regulatory policies impact prices.
2. How does the price of NDC 46122-0754 compare to branded formulations?
Generic prices are approximately 5-6% of brand-name costs, which can exceed USD 800 per vial.
3. What regulatory hurdles exist for new entrants?
FDA approval requires bioequivalence studies, manufacturing inspections, and submission of comprehensive data, which can take 1-2 years.
4. What is the outlook for increased demand?
Cancer incidences are rising globally; however, pricing pressures limit revenue growth potential for existing products.
5. How does market saturation affect future pricing?
Saturation tends to suppress prices, with further reductions mainly driven by new generic entrants and cost efficiencies.
References
[1] Global Oncology Market Size & Share Report, 2022. Market Research Future.
[2] FDA National Drug Code Directory, 2023. U.S. Food and Drug Administration.
[3] IQVIA. (2022). National Prescription Audit.
[4] IMS Health. (2022). Oncology Drug Market Trends.
[5] Statista. (2022). Oncology Drugs Market Revenue Worldwide.
